Sanofi Bulks Up Oncology Development With Avila Collaboration
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.
You may also be interested in...
Avila/Clovis Partnership Moves To The Clinic
Avila and Clovis have selected a drug candidate to move into human testing.
Avila/Clovis Partnership Moves To The Clinic
Avila and Clovis have selected a drug candidate to move into human testing.
Zerhouni Moves Up At Sanofi-Aventis To President Of Global R&D
Former NIH director drafted by Viehbacher in early 2009 to be his science advisor replaces Cluzel as R&D chief.